keyword
MENU ▼
Read by QxMD icon Read
search

Abilify maintena

keyword
https://www.readbyqxmd.com/read/27708677/pharmacoeconomic-comparison-of-aripiprazole-once-monthly-and-paliperidone-palmitate-from-a-head-to-head-clinical-trial-in-schizophrenia-a-us-analysis
#1
Christophe Sapin, Ann Hartry, Siddhesh A Kamat, Maud Beillat, Ross A Baker, Anna Eramo
Schizophrenia presents a substantial clinical and economic burden to the health-care system. In QUAlity of LIfe with AbiliFY Maintena (QUALIFY), a randomized head-to-head study of aripiprazole once-monthly 400 mg (AOM 400) compared with paliperidone palmitate (PP; 78-234 mg/mo), AOM 400 demonstrated greater improvement in health-related quality of life and functioning in patients with stable schizophrenia. The present analysis used health economics assessment data collected during the QUALIFY study to determine the direct medical and pharmacy costs and the cost-effectiveness associated with each treatment over 6 months...
2016: Drugs in Context
https://www.readbyqxmd.com/read/26289486/the-safety-efficacy-and-tolerability-of-abilify-maintena-for-the-treatment-of-schizophrenia
#2
Rene S Kahn, Amalia Giannopoulou
Relapse in schizophrenia has been associated with poor adherence to oral medication. A possible method to optimize medication adherence could be to switch patients from oral to depot medication. In this respect, aripiprazole long acting injectable (ALAI) significantly delayed time to impending relapse when compared with placebo (p < 0.0001), while ALAI was generally well tolerated during both short-term and long-term studies. A literature search, using PubMed was conducted to identify relevant publications...
2015: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/26235040/the-safety-efficacy-and-tolerability-of-abilify-maintena-for-the-treatment-of-schizophrenia
#3
Rene S Kahn, Amalia Giannopoulou
Relapse in schizophrenia has been associated with poor adherence to oral medication. A possible method to optimize medication adherence could be to switch patients from oral to depot medication. In this respect, aripiprazole long acting injectable (ALAI) significantly delayed time to impending relapse when compared with placebo (p < 0.0001), while ALAI was generally well tolerated during both short-term and long-term studies. A literature search, using PubMed was conducted to identify relevant publications...
August 2, 2015: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/24969315/aripiprazole-abilify-maintena%C3%A2-a-review-of-its-use-as-maintenance-treatment-for-adult-patients-with-schizophrenia
#4
REVIEW
Matt Shirley, Caroline M Perry
Aripiprazole (ABILIFY(®)) is an atypical antipsychotic drug that is proposed to act via partial agonism of dopamine D2 receptors. Trials with oral aripiprazole have shown that, compared with some other atypical antipsychotics, aripiprazole is associated with fewer metabolic disturbances and has a favourable cardiovascular tolerability profile. Recently, an intramuscular long-acting injectable (LAI) depot formulation of aripiprazole (ABILIFY MAINTENA(®)) (aripiprazole LAI) has been approved for use as a treatment for schizophrenia in adults...
July 2014: Drugs
https://www.readbyqxmd.com/read/23836344/long-acting-injectable-aripiprazole-abilify-maintena-for-schizophrenia
#5
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
April 29, 2013: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/23644169/long-acting-injectable-aripiprazole-how-might-it-fit-in-our-tool-box
#6
REVIEW
Ganesh Gopalakrishna, Arpit Aggarwal, John Lauriello
Schizophrenia is a severe mental illness with a lifetime prevalence of approximately one percent worldwide. Maintenance antipsychotic treatment has been effective in preventing relapses in long-term follow-up studies. Logically it can be proposed that long-acting injectable antipsychotics (LAI) might reduce both unintentional and intentional nonadherence. Long-acting injectable aripiprazole was approved for the treatment of schizophrenia by the U.S. FDA on 28th February 2013 and will be marketed under the name Abilify Maintena...
2013: Clinical Schizophrenia & related Psychoses
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"